Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 9/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | TK1 | P04183 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6946487 | 0.91 | KMT2A (0.38) | PLA2G7CYP1A2CYP2C19KMT2AMEN1 | |
| SCHEMBL7009479 | 0.88 | PLA2G7 (0.40) | PLA2G7CYP1A2CYP2C19KMT2AMEN1 | |
| SCHEMBL7006453 | 0.84 | PLA2G7 (0.49) | PLA2G7CYP1A2CYP2C19KMT2AMEN1 | |
| SCHEMBL7005649 | 0.84 | PLA2G7 (0.49) | PLA2G7CYP1A2CYP2C19KMT2AMEN1 | |
| SCHEMBL5867433 | 0.84 | TNF (0.43) | PLA2G7 | |
| SCHEMBL7097514 | 0.75 | PLA2G7 (0.43) | PLA2G7CYP1A2CYP2C19KMT2AMEN1 | |
| SCHEMBL7008518 | 0.74 | PLA2G7 (0.44) | PLA2G7CYP1A2CYP2C19CYP2C9HTT | |
| SCHEMBL7012715 | 0.73 | PLA2G7 (0.54) | PLA2G7 | |
| SCHEMBL7012983 | 0.72 | EP300 (0.40) | PLA2G7 | |
| SCHEMBL7010743 | 0.72 | PLA2G7 (0.44) | PLA2G7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1105377-B1 | PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2003-10-08 | — | — | EP | disclosed |
| EP-1028955-B1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 2003-07-16 | — | — | EP | disclosed |
| US-6559155-B1 | Phospholipase A2 enzyme Lipoprotein Associated Phospholipase A2 inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-05-06 | — | — | US | disclosed |
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | HICKEY DEIRDRE MARY BERNADETTE (GB) | 2002-08-29 | — | — | US | disclosed |
| US-6417192-B1 | DRUGS WITH PYRIMIDONE COMPOUNDS INHIBITORS OF THE ENZYME LDL PLA.SUB.2 AND THEREFORE OF USE IN TREATING ATHEROSCLEROSIS. | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-09 | — | — | US | disclosed |
| EP-1105377-A1 | PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2001-06-13 | — | — | EP | disclosed |
| EP-1028955-A1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SmithKline Beecham p.l.c. (GB) | 2000-08-23 | — | — | EP | disclosed |
| WO-2000010980-A1 | PYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS | SMITHKLINE BEECHAM PLC (GB) | 2000-03-02 | — | — | WO | disclosed |
| WO-1999024420-A1 | PYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SMITHKLINE BEECHAM PLC (GB) | 1999-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020120139-A1 | Pyrimidinone compounds and pharmaceutical compositions containing them | PLA2G7, PLA2G1B, PLA2G4C | PLA2G7 1/4885CYP1A2 1351/4885CYP2C19 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.